| Name | Title | Contact Details |
|---|---|---|
Elizabeth Garvin |
Senior VP of Human Resources | Profile |
Kevin Cadman |
Executive Vice President and Chief Financial Officer | Profile |
Amanda Paull |
Head Of Marketing | Profile |
Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.
Mondial Energy Inc. is a Toronto, ON-based company in the Business Services sector.
Cortex HR Inc. is a Toronto, ON-based company in the Business Services sector.
Vojta & Associate is a Stamford, CT-based company in the Business Services sector.
Positive Impact Consulting is a Sacramento, CA-based company in the Business Services sector.